Docebenone might protect experimental acute necrotizing pancreatitis in rats[3]. Docebenone suppresses the release of SRS-A by 55-97%, dose-dependently in doses of 10-8-10-5 M in monkeys. The antigen-induced SRS-A release from these fragments is dose dependently inhibited by 25-93% of Docebenone, with doses of 10-8-10-5 M[4].
